Literature DB >> 15456890

The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature.

Bin Xu1, Robert M deWaal, Nirit Mor-Vaknin, Chris Hibbard, David M Markovitz, Mark L Kahn.   

Abstract

During mammalian vascular development, endothelial cells form a complex array of vessels that differ markedly in structure and function, but the molecular basis for this vascular complexity is poorly understood. Recent insights into endothelial diversity have come from the identification of molecular markers expressed on distinct endothelial cell populations. One such marker, the PAL-E antibody, has been used for almost 20 years to distinguish blood and lymphatic vessels, but the identity of the protein recognized by PAL-E has been unknown. In the present study we have used protein purification and tandem mass spectrometry analysis of tryptic peptides to identify the PAL-E antigen as a secreted form of vimentin. Vimentin has been well characterized as an intracellular intermediate filament protein expressed broadly in mesenchymal cells. In contrast, PAL-E-reactive vimentin is secreted extracellularly, its synthesis is restricted to a distinct population of blood endothelial cells and activated macrophages, and PAL-E-reactive vimentin is found in circulating human blood. PAL-E-reactive vimentin does not arise from an endothelial cell-specific mRNA transcript but is the product of cell-specific posttranslational modification. The PAL-E antibody therefore defines secretion of vimentin as a molecular distinction among endothelial cells and exposes a novel, extracellular role for vimentin in the blood vasculature.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456890      PMCID: PMC517872          DOI: 10.1128/MCB.24.20.9198-9206.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  28 in total

Review 1.  The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature.

Authors:  Guillermo Oliver; Michael Detmar
Journal:  Genes Dev       Date:  2002-04-01       Impact factor: 11.361

Review 2.  Markers for the lymphatic endothelium: in search of the holy grail?

Authors:  J P Sleeman; J Krishnan; V Kirkin; P Baumann
Journal:  Microsc Res Tech       Date:  2001-10-15       Impact factor: 2.769

3.  Widespread occurrence of intermediate-sized filaments of the vimentin-type in cultured cells from diverse vertebrates.

Authors:  W W Franke; E Schmid; S Winter; M Osborn; K Weber
Journal:  Exp Cell Res       Date:  1979-10-01       Impact factor: 3.905

Review 4.  Angiogenesis in health and disease.

Authors:  Peter Carmeliet
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

5.  Vimentin is secreted by activated macrophages.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; David M Markovitz
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

6.  Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.

Authors:  Thomas J Podor; Davindra Singh; Paul Chindemi; Denise M Foulon; Robert McKelvie; Jeffrey I Weitz; Richard Austin; Ghislain Boudreau; Richard Davies
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

7.  Monoclonal antibody PAL-E specific for endothelium.

Authors:  R O Schlingemann; G M Dingjan; J J Emeis; J Blok; S O Warnaar; D J Ruiter
Journal:  Lab Invest       Date:  1985-01       Impact factor: 5.662

8.  Protein kinases required for segregation of vimentin filaments in mitotic process.

Authors:  Y Yasui; H Goto; S Matsui; E Manser; L Lim; M Inagaki
Journal:  Oncogene       Date:  2001-05-24       Impact factor: 9.867

Review 9.  Monoclonal antibody-defined human endothelial antigens as vascular markers.

Authors:  D J Ruiter; R O Schlingemann; F J Rietveld; R M de Waal
Journal:  J Invest Dermatol       Date:  1989-08       Impact factor: 8.551

10.  Electrostatic and hydrophobic interactions of the intermediate filament protein vimentin and its amino terminus with lipid bilayers.

Authors:  G Perides; C Harter; P Traub
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

View more
  52 in total

1.  Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A.

Authors:  Ching-Hui Yang; Jacek Szeliga; Jeremy Jordan; Shawn Faske; Zvjezdana Sever-Chroneos; Bre Dorsett; Robert E Christian; Robert E Settlage; Jeffrey Shabanowitz; Donald F Hunt; Jeffrey A Whitsett; Zissis C Chroneos
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

2.  Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody.

Authors:  David Frescas; Christelle M Roux; Semra Aygun-Sunar; Anatoli S Gleiberman; Peter Krasnov; Oleg V Kurnasov; Evguenia Strom; Lauren P Virtuoso; Michelle Wrobel; Andrei L Osterman; Marina P Antoch; Vadim Mett; Olga B Chernova; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

3.  The intracerebral hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes.

Authors:  Boryana Stamova; Bradley P Ander; Glen Jickling; Farah Hamade; Marc Durocher; Xinhua Zhan; Da Zhi Liu; Xiyuan Cheng; Heather Hull; Alan Yee; Kwan Ng; Natasha Shroff; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-13       Impact factor: 6.200

4.  A novel compound, denosomin, ameliorates spinal cord injury via axonal growth associated with astrocyte-secreted vimentin.

Authors:  Kiyoshi Teshigawara; Tomoharu Kuboyama; Michiko Shigyo; Aiko Nagata; Kenji Sugimoto; Yuji Matsuya; Chihiro Tohda
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

5.  Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions.

Authors:  Emily M Plummer; Diane Thomas; Giuseppe Destito; Leah P Shriver; Marianne Manchester
Journal:  Nanomedicine (Lond)       Date:  2012-03-06       Impact factor: 5.307

6.  Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells.

Authors:  Nicole F Steinmetz; Choi-Fong Cho; Amber Ablack; John D Lewis; Marianne Manchester
Journal:  Nanomedicine (Lond)       Date:  2011-02       Impact factor: 5.307

Review 7.  The roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infections.

Authors:  Amy E Bryant; Clifford R Bayer; Michael J Aldape; Dennis L Stevens
Journal:  Curr Opin Infect Dis       Date:  2015-06       Impact factor: 4.915

8.  Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.

Authors:  Soung-Chul Cha; Hong Qin; Shibichakravarthy Kannan; Seema Rawal; Leticia S Watkins; Flavio E Baio; Weiguo Wu; Juliana Ong; Jinsong Wei; Benjamin Kwak; Sang Kim; Michael S Popescu; Daniel S Paick; Kunhwa Kim; Amber Luong; Richard E Davis; Harry W Schroeder; Larry W Kwak; Sattva S Neelapu
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

9.  Endocytic uptake pathways utilized by CPMV nanoparticles.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Mol Pharm       Date:  2012-09-20       Impact factor: 4.939

10.  Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1.

Authors:  Praveena S Thiagarajan; Valentin P Yakubenko; Deena H Elsori; Satya P Yadav; Belinda Willard; Carmela D Tan; E René Rodriguez; Maria Febbraio; Martha K Cathcart
Journal:  Cardiovasc Res       Date:  2013-05-13       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.